<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265694</url>
  </required_header>
  <id_info>
    <org_study_id>INJE05-06</org_study_id>
    <nct_id>NCT00265694</nct_id>
  </id_info>
  <brief_title>Random Trial for Elderly Patients With NSCLC</brief_title>
  <official_title>A Randomized Phase III Trial of Vinorelbine Versus Gemcitabine and Carboplatin for Elderly Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <brief_summary>
    <textblock>
      1. Recently a radomized trial of vinorelbine versus best supportive care in patients at 70
           years of age or older demonstrated a definite improvement in overall survival rate and
           quality of life with chemotherapy.

        2. The role of combination therapy containing the platinum compound, which is the standard
           therapy for the young patients is still vague.

        3. Gemcitabine and carboplatin have favorable toxicity profile.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Non-Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine, gemcitabine and carboplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathologically confirmed, advanced(clinical stage IIIB or IV) NSCLC

          -  No previous chemotherapy history

          -  Age ≥ 65 years

          -  ECOG performance status ≤ 2

          -  Adequate marrow function (ANC ≥ 2,000/mm3, platelet ≥ 100,000/mm3), renal and liver
             function (total bilirubin &lt; 2.0 mg/dL, AST/ALT levels &lt; 3 × the upper limit of normal,
             serum creatinine &lt; 2.0 mg/dL)

          -  Patients with informed written consent

        Exclusion Criteria:

          -  Patients with other major illness(active infection, severe heart disease, concomitant
             malignancy, etc)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Jin Yuh, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Young Jin Yuh, M.D.</last_name>
    <phone>82-2-950-1460</phone>
    <email>yjyuh@sanggyepaik.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inje University Sanggyepaik Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>139-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Jin Yuh, M.D.</last_name>
      <phone>82-2-950-1460</phone>
      <email>yjyuh@sanggyepaik.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young Jin Yuh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <last_update_submitted>December 14, 2005</last_update_submitted>
  <last_update_submitted_qc>December 14, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

